Addition of Liposomal Bupivacaine to Adductor Canal Block for Post-operative Pain Following Total Knee Arthroplasty

Mikayla E. McGrath BS², Kenneth J. Kress MD¹, Charles A. DeCook MD¹, Jon E. Minter DO¹, Jeffrey P. Garrett MD¹, Mark E. Hamilton MD¹

Arthritis & Total Joint Specialists, Northside Hospital¹
Force Therapeutics²
I (and/or my coauthors) have something to disclose.

Detailed disclosure information is available via:

“My Academy” app

Or

AAOS Orthopaedic Disclosure Program on the AAOS website at http://www.aaos.org/disclosures
Background

• Advances in Multi-Modal Analgesia and motor-sparing regional blocks have revolutionized post-op analgesia for TKA, particularly as same-day discharge (SDD) becomes more prevalent.

• At ASRA 2018, we presented a case report of the use of Liposomal Bupivacaine (LB) for ACB and iPACK (LB-ACB/iPACK) for a complex TKA revision in a patient on significant pre-op chronic narcotics\(^1\). (LB use for ACB is considered off-label at this time but is being done by many practitioners\(^2\).) He had marked pain relief extending 5-6 days.

• After successful adoption of LB-ACB/iPACK for TKR revisions, we elected to trial it as a quality improvement for our primary TKRs.
Methods

• From May through November 2019 medication consumption (narcotic and non-narcotic), pain levels, pain satisfaction and patient data were collected daily for POD 0-7 using our WBRP with 83% overall outcome form compliance.

• This data, patient reported feedback and contemporary physical therapist insights were used to analyze post-operative analgesia and function.

• After receiving baseline information on our standard MMAP 15ml Bupivacaine 0.25% + iPACK - 20ml Bupivacaine 0.25% w epinephrine (Protocol A), quality improvement changes to block formulation based on clinical and patient feedback occurred over an 8-month period.

• Several iterations (Protocol B&C) were trialed until the final protocol of 10mL of LB to 5mL of 0.25% bupivacaine for ACB (Protocol D) maintained decreased narcotic consumption and postoperative pain, with no adverse clinical outcomes.
Methods

PROTOCOL A: STANDARD MMAP
• ACB - 15 ml Bupivacaine 0.25%
• iPACK - 20 ml Bupivacaine 0.25% w epi

PROTOCOL B: LB#1
• ACB - 15 ml LB + 5 ml Bupivacaine 0.5 %
• iPACK - 5 ml LB + 15 ml Bupivacaine 0.25%.

PROTOCOL C: LB#2
• ACB - 10 ml LB + 5 ml Bupivacaine 0.5%
• iPACK = 20 ml Bupivacaine 0.25% w epi

PROTOCOL D: LB#3
• ACB = 10 ml LB + 5 ml Bupivacaine 0.25%
• iPACK = 20 ml Bupivacaine 0.25% w epi
Results

• Protocols A(N= 130) and D(N=132) were compared in final analysis. No significant differences at baseline between groups.

• Protocol D resulted in improved analgesia demonstrated by 44% decrease in daily use of oxycodone 5mg pills POD 1-7 (1.05 to 0.59 pills/ day, p=<0.01), 43% decrease in total oxycodone 5mg pills over POD 0-7 (7.48 to 4.25, p<0.01), and increase in patients taking 0 narcotic pills POD 0-7 (25% to 38%).

• There was no difference in 12-week postoperative Knee Injury and Osteoarthritis Outcome Score Jr. (p=0.39), Veterans Rand 12 Physical (p=0.10) or Mental Component Scores (p=0.12).
Results

Postoperative Daily Narcotic Use - # of Oxycodone 5mg per day

- STANDARD MMAP
- STANDARD + LB / ACB

43% Average Reduction in Weekly Total Oxycodone 5mg pills
Discussion & Conclusion

• As Total Knee Arthroplasty moves to SDD, it will become even more important and challenging to control pain post-discharge. In the opioid crisis era, this needs to be done while decreasing reliance on narcotics.

• The addition of LB 10 ml to the ACB with our Standard MMAP accomplished an even further reduction in post-op narcotic use with 43% reduction in narcotic use POD 1-7 and an increase from 25% to 38% who required ZERO narcotics POD 1-7.

• With an already aggressive MMAP and low narcotic usage, the addition of LB to ACB significantly decreased TKA postoperative narcotic usage POD 1-7.